Marianne Pavel
Overview
Explore the profile of Marianne Pavel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
5267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prasad V, Koumarianou A, Denecke T, Sundin A, Deroose C, Pavel M, et al.
J Neuroendocrinol
. 2024 Dec;
37(2):e13479.
PMID: 39653582
Assessing the response to systemic therapy in neuroendocrine tumors (NET) is challenging since morphological imaging response is often delayed and not necessarily reflective of clinical benefit. Peptide receptor radionuclide therapy...
2.
Kasajima A, Pfarr N, Mayr E, Ura A, Moser E, von Werder A, et al.
Endocr Pathol
. 2024 Oct;
35(4):313-324.
PMID: 39382626
Little is known about the morphomolecular features of G3 neuroendocrine tumors (G3NETs) under prolonged systemic treatments, although rapid progression is increasingly observed. This longitudinal study aims to elucidate the course...
3.
Fueermann F, Heller K, Pavel M, Herbst L, Grutzmann R, Schiffer M
Am J Transplant
. 2024 Aug;
24(11):2125-2128.
PMID: 39094952
Patients with type 1 diabetes and concurrent subcutaneous insulin resistance present unique diagnostic and therapeutic challenges for clinicians. The standard therapeutic approach is the administration of intravenous insulin. Pancreatic transplantation...
4.
Auzanneau M, Seufert J, Zimny S, Haak T, Zeyfang A, Golz S, et al.
Diabetes Obes Metab
. 2024 Jul;
26(9):4116-4120.
PMID: 38982585
No abstract available.
5.
Lamarca A, Bartsch D, Caplin M, Kos-Kudla B, Kjaer A, Partelli S, et al.
J Neuroendocrinol
. 2024 Jul;
36(9):e13423.
PMID: 38977327
Both the incidence and prevalence of well-differentiated neuroendocrine tumours from the small intestine (Si-NET) are gradually increasing. Most patients have non-functioning tumours with subtle GI symptoms and tumours are often...
6.
Lahner H, Pavel M
Inn Med (Heidelb)
. 2024 Jun;
65(7):664-671.
PMID: 38900278
Gastrointestinal neuroendocrine tumours (NETs) are rare and clinically heterogeneous. From a diagnostic perspective, well-differentiated tumours must be distinguished from poorly differentiated neuroendocrine carcinomas. The disease may be associated with autonomous...
7.
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz P, et al.
Lancet
. 2024 Jun;
403(10446):2807-2817.
PMID: 38851203
Background: There are currently no standard first-line treatment options for patients with higher grade 2-3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line...
8.
Cuba L, Durr P, Gessner K, Hacker B, Fietkau R, Siebler J, et al.
JCO Oncol Pract
. 2024 Jun;
20(9):1219-1230.
PMID: 38848539
Purpose: Implementation science endeavors to facilitate the translation of evidence-based research into clinical routine. The clinical pharmacological/pharmaceutical care program evaluated in the randomized AMBORA trial on medication safety with oral...
9.
Lamberti G, Panzuto F, Pavel M, OToole D, Ambrosini V, Falconi M, et al.
Nat Rev Dis Primers
. 2024 Apr;
10(1):25.
PMID: 38605021
Gastric neuroendocrine neoplasms (gNENs) display peculiar site-specific features among all NENs. Their incidence and prevalence have been rising in the past few decades. gNENs comprise gastric neuroendocrine carcinomas (gNECs) and...
10.
Pavel M, Lahner H, Horsch D, Rinke A, Denecke T, Koch A, et al.
Oncologist
. 2024 Jan;
29(5):e643-e654.
PMID: 38206830
Background: In advanced neuroendocrine tumors (NET), antiproliferative treatment options beyond somatostatin analogs remain limited. Temozolomide (TMZ) has shown efficacy in NET alone or combined with other drugs. Materials And Methods:...